Abstract
The treatment of rheumatoid arthritis (RA) in the last decade has made enormous advances with the use of biological therapies. However, these therapies have serious limitations such as the expense, side-effects, and the requirement for repeated injections, each of which can potentially be obviated by gene therapy. A gene therapy approach for the treatment of RA has the potential to stably deliver a gene product or multiple products in a target-specific, disease-inducible manner. There are many studies investigating gene therapy in RA, the majority of which have been designed to test proofof- principle in an animal model. With an abundance of animal studies that have established much promise, the field is now at the early stage of moving towards human trials, where patient benefit needs to overshadow associated risks, especially since RA is publicly perceived as a non-life-threatening disease. Here, we provide an overview that focuses on advances in the application of gene therapy to RA over the last five years, including: novel targets and approaches; the viral and non-viral applications most likely to succeed in the clinic; advances in our understanding of the contralateral effect; the latest successes with anti-inflammatory cytokines; and a review of advancements towards clinical trials.
Keywords: Adeno-associated virus, Angiogenesis, Animal models, Apoptosis, Contralateral effect, Electrotransfer, Interleukin-10, Signaling
Current Gene Therapy
Title: Gene Therapy for Rheumatoid Arthritis: Recent Advances
Volume: 8 Issue: 1
Author(s): James M. Woods, Yasmin Sitabkhan and Alisa E. Koch
Affiliation:
Keywords: Adeno-associated virus, Angiogenesis, Animal models, Apoptosis, Contralateral effect, Electrotransfer, Interleukin-10, Signaling
Abstract: The treatment of rheumatoid arthritis (RA) in the last decade has made enormous advances with the use of biological therapies. However, these therapies have serious limitations such as the expense, side-effects, and the requirement for repeated injections, each of which can potentially be obviated by gene therapy. A gene therapy approach for the treatment of RA has the potential to stably deliver a gene product or multiple products in a target-specific, disease-inducible manner. There are many studies investigating gene therapy in RA, the majority of which have been designed to test proofof- principle in an animal model. With an abundance of animal studies that have established much promise, the field is now at the early stage of moving towards human trials, where patient benefit needs to overshadow associated risks, especially since RA is publicly perceived as a non-life-threatening disease. Here, we provide an overview that focuses on advances in the application of gene therapy to RA over the last five years, including: novel targets and approaches; the viral and non-viral applications most likely to succeed in the clinic; advances in our understanding of the contralateral effect; the latest successes with anti-inflammatory cytokines; and a review of advancements towards clinical trials.
Export Options
About this article
Cite this article as:
Woods M. James, Sitabkhan Yasmin and Koch E. Alisa, Gene Therapy for Rheumatoid Arthritis: Recent Advances, Current Gene Therapy 2008; 8 (1) . https://dx.doi.org/10.2174/156652308783688482
DOI https://dx.doi.org/10.2174/156652308783688482 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Antiinflammatory Treatment for Seemingly Non-inflammatory Disorders-Part 2)
Endocrine, Metabolic & Immune Disorders - Drug Targets Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Review of Current Knowledge of the Complement System and the Therapeutic Opportunities in Inflammatory Arthritis
Current Medicinal Chemistry Adenosine Deaminase Activity and HLA-DRB as Diagnostic Markers for Rheumatoid Arthritis
Current Rheumatology Reviews Molecular Design and Clinical Development of VEGFR Kinase Inhibitors
Current Topics in Medicinal Chemistry Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Total Synthesis and Analgesic Activity of 6-Fluoroindan-1-acetic Acid and its 3-Oxo Derivative
Medicinal Chemistry Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Anti-cytokines and Cytokines in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Drug Repurposing: Translational Pharmacology, Chemistry, Computers and the Clinic
Current Topics in Medicinal Chemistry Biological Importance, Therapeutic Benefit and Analytical Aspects of Bioactive Flavonoid Pectolinarin in the Nature
Drug Metabolism Letters A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design